vs
Side-by-side financial comparison of Dine Brands Global, Inc. (DIN) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.
Dine Brands Global, Inc. is the larger business by last-quarter revenue ($217.6M vs $158.6M, roughly 1.4× Stoke Therapeutics, Inc.). Stoke Therapeutics, Inc. runs the higher net margin — 71.2% vs -5.6%, a 76.8% gap on every dollar of revenue. On growth, Stoke Therapeutics, Inc. posted the faster year-over-year revenue change (3661.1% vs 6.3%). Stoke Therapeutics, Inc. produced more free cash flow last quarter ($131.7M vs $-8.6M).
Dine Brands Global Inc. is a publicly traded food and beverage company based in Pasadena, California. Founded in 1958 as IHOP, it operates franchised and corporate owned full-service restaurants including three restaurant concepts, Applebee's Neighborhood Grill & Bar, International House of Pancakes (IHOP), and Fuzzy's Taco Shop.
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
DIN vs STOK — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $217.6M | $158.6M |
| Net Profit | $-12.2M | $112.9M |
| Gross Margin | 42.4% | — |
| Operating Margin | -7.6% | 70.2% |
| Net Margin | -5.6% | 71.2% |
| Revenue YoY | 6.3% | 3661.1% |
| Net Profit YoY | -336.1% | 528.0% |
| EPS (diluted) | $-0.79 | $1.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $217.6M | — | ||
| Q3 25 | $216.2M | — | ||
| Q2 25 | $230.8M | — | ||
| Q1 25 | $214.8M | $158.6M | ||
| Q4 24 | $204.8M | $22.6M | ||
| Q3 24 | $195.0M | — | ||
| Q2 24 | $206.3M | — | ||
| Q1 24 | $206.2M | — |
| Q4 25 | $-12.2M | — | ||
| Q3 25 | $7.3M | — | ||
| Q2 25 | $13.8M | — | ||
| Q1 25 | $8.2M | $112.9M | ||
| Q4 24 | $5.2M | $-10.5M | ||
| Q3 24 | $19.1M | — | ||
| Q2 24 | $23.2M | — | ||
| Q1 24 | $17.5M | — |
| Q4 25 | 42.4% | — | ||
| Q3 25 | 39.1% | — | ||
| Q2 25 | 40.0% | — | ||
| Q1 25 | 42.0% | — | ||
| Q4 24 | 41.7% | — | ||
| Q3 24 | 47.8% | — | ||
| Q2 24 | 48.1% | — | ||
| Q1 24 | 47.2% | — |
| Q4 25 | -7.6% | — | ||
| Q3 25 | 4.7% | — | ||
| Q2 25 | 8.2% | — | ||
| Q1 25 | 6.0% | 70.2% | ||
| Q4 24 | 3.8% | -60.4% | ||
| Q3 24 | 13.6% | — | ||
| Q2 24 | 15.1% | — | ||
| Q1 24 | 11.7% | — |
| Q4 25 | -5.6% | — | ||
| Q3 25 | 3.4% | — | ||
| Q2 25 | 6.0% | — | ||
| Q1 25 | 3.8% | 71.2% | ||
| Q4 24 | 2.5% | -46.4% | ||
| Q3 24 | 9.8% | — | ||
| Q2 24 | 11.2% | — | ||
| Q1 24 | 8.5% | — |
| Q4 25 | $-0.79 | — | ||
| Q3 25 | $0.48 | — | ||
| Q2 25 | $0.89 | — | ||
| Q1 25 | $0.53 | $1.90 | ||
| Q4 24 | $0.35 | $-0.15 | ||
| Q3 24 | $1.24 | — | ||
| Q2 24 | $1.50 | — | ||
| Q1 24 | $1.13 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $128.2M | $274.8M |
| Total DebtLower is stronger | $1.2B | — |
| Stockholders' EquityBook value | $-273.9M | $350.1M |
| Total Assets | $1.7B | $406.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $128.2M | — | ||
| Q3 25 | $167.9M | — | ||
| Q2 25 | $194.2M | — | ||
| Q1 25 | $186.5M | $274.8M | ||
| Q4 24 | $186.7M | $128.0M | ||
| Q3 24 | $169.6M | — | ||
| Q2 24 | $153.5M | — | ||
| Q1 24 | $145.0M | — |
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.2B | — | ||
| Q1 24 | $1.2B | — |
| Q4 25 | $-273.9M | — | ||
| Q3 25 | $-231.9M | — | ||
| Q2 25 | $-212.5M | — | ||
| Q1 25 | $-215.7M | $350.1M | ||
| Q4 24 | $-216.0M | $229.0M | ||
| Q3 24 | $-216.7M | — | ||
| Q2 24 | $-231.7M | — | ||
| Q1 24 | $-244.8M | — |
| Q4 25 | $1.7B | — | ||
| Q3 25 | $1.8B | — | ||
| Q2 25 | $1.8B | — | ||
| Q1 25 | $1.8B | $406.9M | ||
| Q4 24 | $1.8B | $271.6M | ||
| Q3 24 | $1.7B | — | ||
| Q2 24 | $1.7B | — | ||
| Q1 24 | $1.7B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $5.7M | $131.8M |
| Free Cash FlowOCF − Capex | $-8.6M | $131.7M |
| FCF MarginFCF / Revenue | -3.9% | 83.0% |
| Capex IntensityCapex / Revenue | 6.6% | 0.1% |
| Cash ConversionOCF / Net Profit | — | 1.17× |
| TTM Free Cash FlowTrailing 4 quarters | $53.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.7M | — | ||
| Q3 25 | $30.2M | — | ||
| Q2 25 | $37.0M | — | ||
| Q1 25 | $16.1M | $131.8M | ||
| Q4 24 | $30.5M | $-23.2M | ||
| Q3 24 | $25.5M | — | ||
| Q2 24 | $21.6M | — | ||
| Q1 24 | $30.6M | — |
| Q4 25 | $-8.6M | — | ||
| Q3 25 | $18.1M | — | ||
| Q2 25 | $31.0M | — | ||
| Q1 25 | $12.8M | $131.7M | ||
| Q4 24 | $26.7M | $-23.2M | ||
| Q3 24 | $22.0M | — | ||
| Q2 24 | $18.2M | — | ||
| Q1 24 | $27.2M | — |
| Q4 25 | -3.9% | — | ||
| Q3 25 | 8.4% | — | ||
| Q2 25 | 13.4% | — | ||
| Q1 25 | 6.0% | 83.0% | ||
| Q4 24 | 13.0% | -102.7% | ||
| Q3 24 | 11.3% | — | ||
| Q2 24 | 8.8% | — | ||
| Q1 24 | 13.2% | — |
| Q4 25 | 6.6% | — | ||
| Q3 25 | 5.6% | — | ||
| Q2 25 | 2.6% | — | ||
| Q1 25 | 1.5% | 0.1% | ||
| Q4 24 | 1.9% | 0.2% | ||
| Q3 24 | 1.8% | — | ||
| Q2 24 | 1.7% | — | ||
| Q1 24 | 1.6% | — |
| Q4 25 | — | — | ||
| Q3 25 | 4.12× | — | ||
| Q2 25 | 2.68× | — | ||
| Q1 25 | 1.97× | 1.17× | ||
| Q4 24 | 5.88× | — | ||
| Q3 24 | 1.34× | — | ||
| Q2 24 | 0.93× | — | ||
| Q1 24 | 1.75× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DIN
| Franchisor | $163.2M | 75% |
| Food And Beverage | $27.3M | 13% |
| Proprietary Product Sales And Other | $17.0M | 8% |
| Other | $8.1M | 4% |
| Franchise And Development Fees | $2.0M | 1% |
STOK
Segment breakdown not available.
